scholarly article | Q13442814 |
P50 | author | Hyun Cheol Chung | Q59647646 |
Makoto Tahara | Q89747698 | ||
Yung-Jue Bang | Q16180903 | ||
P2093 | author name string | Kenichi Takahashi | |
Jonathan D Cheng | |||
Bhumsuk Keam | |||
Yasuhisa Hasegawa | |||
Chia-Chi Lin | |||
Kei Muro | |||
P2860 | cites work | Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. | Q38959172 |
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study | Q39084242 | ||
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. | Q39193035 | ||
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck | Q43164702 | ||
Pemetrexed in combination with cisplatin versus cisplatin monotherapy in East Asian patients with recurrent or metastatic head and neck cancer: Results of an exploratory subgroup analysis of a phase III trial | Q44523490 | ||
Analysis of risk factors of predictive local tumor control in oral cavity cancer | Q80424493 | ||
Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: Results of an open-label, single-arm, multicenter trial | Q87633710 | ||
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
The synergistic effect of chemical carcinogens enhances Epstein-Barr virus reactivation and tumor progression of nasopharyngeal carcinoma cells | Q28483778 | ||
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
Platinum-based chemotherapy plus cetuximab in head and neck cancer | Q33381094 | ||
Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia | Q36239931 | ||
Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. | Q36764761 | ||
Treatment of recurrent metastatic head and neck cancer: focus on cetuximab | Q37218978 | ||
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. | Q38119732 | ||
State-of-the-art and emerging treatment options in the management of head and neck cancer: news from 2013. | Q38211309 | ||
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. | Q38393045 | ||
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial | Q38829062 | ||
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial | Q38849759 | ||
Global Epidemiology of Head and Neck Cancers: A Continuing Challenge. | Q38860198 | ||
P433 | issue | 3 | |
P921 | main subject | pembrolizumab | Q13896859 |
head and neck squamous cell carcinoma | Q18348812 | ||
P304 | page(s) | 771-776 | |
P577 | publication date | 2018-02-08 | |
P1433 | published in | Cancer Science | Q326125 |
P1476 | title | Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012 | |
P478 | volume | 109 |